Cervical Cancer and Tumor Growth Assessment
Author Information
Author(s): D.J. Cole, D.C. Brown, E. Crossley, C.J. Alcock, K.C. Gatter
Primary Institution: Churchill Hospital, Oxford; Nuffield Department of Pathology, John Radcliffe Hospital, Oxford, UK
Hypothesis
Does assessing the growth fraction of cervical carcinoma using antibody Ki-67 provide valuable prognostic information?
Conclusion
The study found no significant relationship between tumor growth fraction and survival or other clinical parameters in cervical carcinoma.
Supporting Evidence
- The study involved 28 patients with cervical carcinoma.
- Immunocytochemistry was performed using the Ki-67 antibody.
- No significant relationship was found between Ki-67 staining and survival.
- Half of the patients had advanced disease at FIGO stage II or more.
Takeaway
The study looked at whether a special test could help predict how cervical cancer would behave, but it didn't find any useful information.
Methodology
The study used immunocytochemistry with the Ki-67 antibody to assess tumor growth in cervical cancer patients.
Limitations
The small sample size and the potential non-representative sampling of tumor cells may have affected the results.
Participant Demographics
The study included 28 patients with cervical carcinoma, consisting of 6 adenocarcinomas and 22 squamous cell carcinomas.
Want to read the original?
Access the complete publication on the publisher's website